GB1598915A - 1,4-dihydro-quinoline-3-carboxylic acid derivatives process for their preparation and composition containing them - Google Patents

1,4-dihydro-quinoline-3-carboxylic acid derivatives process for their preparation and composition containing them Download PDF

Info

Publication number
GB1598915A
GB1598915A GB39197/77A GB3919777A GB1598915A GB 1598915 A GB1598915 A GB 1598915A GB 39197/77 A GB39197/77 A GB 39197/77A GB 3919777 A GB3919777 A GB 3919777A GB 1598915 A GB1598915 A GB 1598915A
Authority
GB
United Kingdom
Prior art keywords
oxo
quinoline
dihydro
carboxylic acid
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB39197/77A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoire Roger Bellon SA
Original Assignee
Laboratoire Roger Bellon SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire Roger Bellon SA filed Critical Laboratoire Roger Bellon SA
Priority to GB39197/77A priority Critical patent/GB1598915A/en
Priority to SE7809411A priority patent/SE444566B/en
Priority to FR7825937A priority patent/FR2403339A1/en
Priority to CA000311364A priority patent/CA1175836A/en
Priority to US05/942,635 priority patent/US4292317A/en
Priority to ES473486A priority patent/ES473486A1/en
Priority to AU39962/78A priority patent/AU520458B2/en
Priority to BE2057287A priority patent/BE870576A/en
Priority to JP11471278A priority patent/JPS5466686A/en
Priority to NLAANVRAGE7809591,A priority patent/NL190520C/en
Priority to DE19782840910 priority patent/DE2840910A1/en
Publication of GB1598915A publication Critical patent/GB1598915A/en
Priority to FR8120346A priority patent/FR2498931A1/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)

Description

(54) 1,4-DIHYDRO-QUINOLINE-3-CARBOXYLIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM (71) We, LABORATOIRE ROGER BELLON S.A., a French body corporate, of 159, avenue du Roule, 92201 Neuilly-sur-Seine, France, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:- This invention is concerned with certain novel 1,4-dihydro-quinoline-3-carboxylic acid derivatives, with a process for their preparation, and with compositions containing them.
It is known that l-alkyl-7-dialkylamino-4-oxo-1,4-dihydro-quinoline-3-carboxylic acids are anti-bacterial agents. Compounds of this type, which have a piperazinyl radical or a 4-substituted piperazinyl radical as the dialkylamino grouping, are described in French Patent 2,210,413. The corresponding compounds which contain a vinyl radical as the l-substituent have the same properties and form the subject of French Patent 2,257,292.
We have now unexpectedly found that the introduction into the above-mentioned compounds of a halogen atom (in particular chlorine or fluorine) in the 6-position, gives new derivatives which are more active and possess a broader spectrum of antibacterial activity. These halogeno derivatives are active at low concentrations against both Gram positive and Gram negative bacteria and thus constitute valuable agents for the treatment of infectious human or animal diseases. They can also be used as growth factors in animals by addition to their feed.
According to the present invention, therefore, there are provided 6-halogena-1- substituted - 7 - disubstituted - amino - 4 - oxo - 1,4 - dihydro - quinoline - 3carboxylic acids of formula 1:
in which R1 is an alkyl group having up to 5, preferably 1 or 2, carbon atoms, an aralkyl group in which the alkyl group contains up to 5 carbon atoms, such as benzyl a vinyl or allyl group, or a hydroxyalkyl or halogenoalkyl group having up to 5 carbon atoms R2 and Ra are each an alkyl group having up to 5 carbon atoms or together with the nitrogen atom to which they are attached, form a 5- or 6-membered hetero cyclic ring containing the nitrogen atom and, optionally another heteroatom, which heterocyclic ring may optionally be substituted, and X is a halogen atom, preferably chlorine, bromine or fluorine, provided that R2 and R, do not form an unsubstituted piperazinyl group when R1 is ethyl and X is fluorine, and their physiologically acceptable acid addition salts, such as the hydrochloride, maleateq and methanesulphonate.
When R2 and R3 form a heterocyclic ring, they preferably form a pyrrolidino, piperidino, morpholino or piperazinyl group, which may be substituted or unsubstituted.
A preferred class of substituted heterocyclic groups are 4-substituted piperazinyl groups of the formula
in which n is an integer from 0 to 3, R4 is a hydrogen atom, a hydroxyl group (provided n is 2 or 3), an unsubstituted or substituted phenyl group, a vinyl group (provided n is 1, 2 or 3) or a formyl or acetyl group. Preferred values of Rr(CH2)n- are methyl, fi-hydroxyethyl, allyl, formyl, phenyl and henzyl.
The present invention also comprises a process for the preparation of a compound according to the invention, which comprises condensing a secondary amine of the formula:
in which R2 and Ra have the above-stated meanings, with a 1-substituted-6-halogeno 7-chloro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid of the formula:
in which R1 and X have the above-stated meanings, provided that Ra and Ra do not form an unsubstituted piperazinyl group when R1 is ethyl and X is fluorine.
The condensation reaction is selective and occurs only at the chlorine atom in the 7-position of the starting compound III. Thus, when X is Cl, if the product of the reaction is subjected to catalytic hydrogenation in an alkaline medium in the presence of palladium on charcoal, the corresponding l-substituted-7-disubstituted-amino-4-oxo- 1,4-dihydro-quinoline-3-carboxylic acid is obtained as the exclusive product.
The reaction of the dihalogeno-acid III with the amine II is preferably carried out by heating the two reactants in substantially equimolar proportions in the presence of an acceptor for the hydracid which is formed in the reaction.
The acid acceptors may be either an inorganic acceptor, such as an alkali metal carbonate, or, preferably, an organic acceptor, such as a tertiary alkFlamine, for example triethylamine or tributylamine. In the latter case, a slight excess (1.1 to 1.5 mols) of secondary amine and a considerable excess (2 to 10 molecules; of the tertiary amine are used per mole of the dihalogeno-acid III.
The hydracid acceptor may also be an excess of the secondary base used in the reaction; for example 2 to 10 mols of secondary amine R2R3NH can be used per mol of the dihalogeno-acid III.
As the chlorine atom in the 7-position of the dihalogeno-acid III is relatively unreactive, it is desirable to carry out the reaction at a temperature of from 100 to 200"C, more preferably from 110 to 1500C, in order to obtain sufficiently fast reaction rates.
In order to follow the reaction, it is desirable to carry out the reaction in a solvent which is such that the mixture remains homogeneous after dissolution of the dihalogenoacid III. Sampling of the reaction mixture then enables the amount of ionised chlorine formed to be determined and thus the course of the reaction. For this purpose, solvents with a boiling point of at least 1000C are preferably used. Suitable solvents are, for example, aliphatic alcohols, glycol, glycol ethers (such as methyl Cellosolve), dimethylformamide, dimethylacetamide and dimethylsulphoxide ("Cellosolve" is a Trade Mark).
When the secondary amine used is piperazine, with the object of obtaining a monosubstituted piperazine derivative (R4 = H, n = 0 in the above partial formula), it is necessary, when using the above-mentioned solvents, to use a large excess of piperazine (6 to 10 mols per mol of dihalogeno-acid). Despite this precaution, mbre or less significant amounts of the N,N'-disubstituted piperazine derivative are always formed, which reduces the yield of the desired monosubstituted derivative and renders its isolation and purification more difficult.
We have found that the selectivity of the reaction can be very substantially improved in this case by the use of pyridine or a methylated derivative thereof (picoline, lutidine or collidine) as the solvent The preferred use of pyridine or such a derivative enables rhe formation of N,N'-disubstituted piperazine derivatives to be very substantially reduced and also avoids the necessity for using a large excess of piperazine. Using pyridine or a methyl derivative thereof as the solvent and under the temperature conditions mentioned above, the use of from 2 to 5 mols of piperazine per mol of dihalogeno-acid III enables the reaction to be completed in 4 to 10 hours.
This same solvent, i.e. pyridine or methyl derivative, can, of course, also be used for reactions with secondary amines other than piperazine.
Mixtures of two or more of the solvents mentioned above can also be used.
In the case where the amine used has a boiling point which is lower than the temperature necessary for the reaction, the latter should be carried out in an autoclave.
The amounts of solvent (or solvent mixture) used is preferably such that the concentration of the reactants therein is from 10 to 30%.
For reaction temperatures of from 110 to 1500C, the reaction time depends on the reactivity of the base; for any given case, at least 90% of the chlorine is removed in the ionised form in reaction times of from 2 to 20 hours.
The isolation of the reaction product depends on its own physico-chemical characteristics and on those of the solvent (or solvents) used. According to these factors, the following situations can arise: a) following dissolution of the reactants in the solvent, the reaction product precipitates during the course of the reaction; or b) the reaction product crystallises from the mixture during or after the cooling of the latter to room temperature.
In both these cases, the reaction mixture is cooled, diluted, if appropriate, with water or a lower alcohol, and the solid product is filtered off. c) the product remains in solution after cooling.
In this case, the reaction mixture is concentrated to dryness. The residue is taken up in water, which usually leads to partial precipitation of the product. The strongly alkaline mixture is brought to pH 7-7.5 by the addition of an inorganic or organic acid, and the precipitate is filtered off.
In a variant of this procedure, the reaction product, after the mixture has been concentrated and the residue taken up in water, is totally dissolved by the addition of an alkali metal hydroxide solution. The solution thus obtained sometimes exhibits slight turbidity which is caused by the presence of non-acidic substances; these substances are then removed by filtration, optionally in the presence of animal charcoal, or by extraction with an appropriate solvent. The alkalien solution is brought to pH 7-7.5, and the reaction product is isolated as indicated previously.
After neutralisation, the solid can optionally be extracted with a suitable solvent.
After concentration of the extract, the crude product is then obtained, which is purified by recrystallisation from an appropriate solvent, as in the preceding cases.
When Rl in formula I is a vinyl group, the compounds according to the invention can be prepared by either of two processes depending on whether the vinyl substituent in the l-position is introduced at the beginning of the synthesis process (process A) or at the end of the process (process B). The reaction schemes below show the stages of these two processes for the case where X in formula I is fluorine. The two methods use 7 - chloro - 3 - ethoxycarbonyl - 6 - fluoro - 1 - (2 - hydroxyethyl) - 4 - oxo1,4-dihydro-quinoline (V) as an intermediate. The intermediate V is obtained by the alkylation of 7 - chloro - 3 - ethoxycarbonyl - 6 - fluoro - 4 - oxo - 1,4 - dihydrc- quinoline (IV) with a 2-halogeno-ethanol XCH2-CH2OH, in which X is a halogen atom, in the presence of a base, for example a neutral alkali metal carbonate. The reaction is suitably carried out at a temperature of from 100" to 1209C, preferably in dimethylformamide (DAIF). For each mole of the ester IV, in solution in 5 to 10 times its weight of DMF, an excess of alkali metal carbonate (2 to 3 moles) and an excess of halogeno-ethanol (4 moles) are preferably used. The reaction is complete when the pH of the reaction medium becomes neutral, which, when using bromoethanol, is generally obtained after 4 hours of heating. When chloroethanol is used as the alkylation agent, it is preferred to carry out the reaction in the presence of an alkali metal bromide, such as potassium bromide, in order to increase the reaction rate, the bromide suitably being used in a proportion of 0.1 to 1.0 mole per mole of chioroethanol. After concentration under reduced pressure and dilution with water, the ester V, m.p. 2020 C, precipitates; it is then dried and recrystallised from a suitable solvent
In Process A the ester V is halogenated by any suitable known process, preferably with thionyl chloride, to form 7-chloro-1-(2-chloroethyl)-3-ethoxycarbonyl-6fluoro-4-oxo-1,4-dihydro-quinoline (VI), m.p. 222 C. The latter, heated with an excess of alkali metal hydroxide in aqueous alcoholic gives, after acidification, 7 - ehloro - 6 - fluoro - 4 - oxo -1 - vinyl -1,4 - dihydro - quinoline - 3 - carboxylic acid (VII), m.p. 2100 C. On heating the latter, under the conditions previously described, with a secondary amine HNR2R,, a compound according to the invention (VIII) in which the substituent R1 is a vinyl group, is obtained. The product is isolated and purified by the methods described above.
Contrary to what has previously been described for compounds of formula I in which R1 is an alkyl group having up to 5 carbon atoms, the conversion of compound VII to compound VIII is, in the case of Process A, more complex. The quantity of chloride ions formed, whatever the reaction conditions, seldom exceeds 60% of theory and the reaction products VIII are only obtained in relatively low yields.
In Process B, the ester V is saponified with an alkali metal hydroxide and the mixture is acidified to give 7 - chloro - 6 - fluoro - 1 - (2 - hydroxyethyl) - 4 oxo-1,4-dihydro-quinoline-3-carboxylic acid (IX), m.p. 2660 C. The latter is treated with an excess of a secondary amine HNR2R3, under the conditions previously described, to give 7 - dialkylamino - 6 - fluoro - 1 - (2 - hydroxyethyl) - 4 - oxo 16-dihydroquinoline-3-carboxylic acid (X). The latter is chlorinated with thionyl chloride, preferably at reflux temperature for 2 to 4 hours, to give, after evaporation of the excess reactant and taking up the residue in ethanol, 7-dialkylamino-3-ethoxycarbonyl - 1 - (2 - chloroethyl) - 6 - fluoro - 4 - oxo - 1,4 - dihydro - quinoline (XI). Saponification of the ester XI with an aqueous alcoholic solution of an alkali metal hydroxide gives, after neutralisation, a compound according to the invention, VIII, in which R1 is a vinyl group.
Process B is generally preferred over Process A and the latter is, in practice, only used when the R2RsN-radical contains functions which are sensitive to the thionyl chloride used in the stage X to XI of process B.
In order that the invention may be more fully understood, the following examples are given by way of illustration. The melting points indicated were determined on a Kofler block for temperatures up to 260"C, and on a Maqueime block for temperatures above 2600 C. Except where specifically indicated, the analyses mentioned were carried out on the products after drying at 1500C in vacuo (5 mm Hg).
Example 1.
6 - Chloro - 1 - ethyl - 7 - (4 - methylpiperazinyl) - 4 - 010 - 1,4 - dihydro- quinoline - 3 - carboxylic acid.
A solution of 4.3 g of 6,7 - dichloro - I - ethyl - 4 - oxo - 1,4 - dihydroquinoline - 3 - carboxylic acid and 9 g of l-methylpiperazine in 45 cm3 of dimethylsulphoxide was stirred and heated to 1 100C. Determination of the Cl ions in the mixture showed that 80% of the theoretical amount of halogen (for the removal of one Cl atom) was in the ionised form after 4 hours of heating. The heating and stirring were continued for a further 3 hours. The reaction product crystallised on cooling. It was filtered off, washed with ethanol and recrystallised from 40 cm3 of methyl Cellosolve.
2.7 g of 6 - chloro -1 - ethyl - 7 - (4 - methylpiperazinyl) - 4 - oxo - 1,4dihydro - quinoline - 3 - carboxylic acid were obtained; m.p. = 2600 C.
Analysis for C17H,, CINsO, (molecular weight 349.8) Calculated % C 58.36 H 5.76 N 12.01 Cl 10.13 Found % C 58.12 H 5.70 N 12.00 Cl 10.48 Identification 1.75 g of this acid were dissolved in 30 cm' of 70% aqueous ethanol in the presence of 5 cm" of N sodium hydroxide and 1.4 cm3 of triethylamine were added.
The solution thus obtained was stirred in a hydrogen atmosphere at atmospheric pressure and room temperature (23"C) in the presence of 0.8 g of 5% palladiumon-charcoal which had been previously saturated in the presence of 5 cm3 of ethanol.
Absorption (135 cm3; theoretical volume for 1 mol: 121 cm3) ceased after 2 hours 30 minutes. The solution was filtered and concentrated to dryness in vacuo. The residue was dissolved in 20 cm3 of water and mixed with 0.3 cm3 of acetic acid.
The precipitate (hydrochloride) was recrystallised from 10(4 cm3 of a saturated aqueous solution of sodium acetate. The solid was filtered off and recrystallised from methyl Cellosolve. 0.65 g of 1 - ethyl - 7 - (4 - methylpiperazinyl) - 4 - oxo - 1,4 - dihydroquinoline - 3 - carboxylic acid, m.p. 215"C, were obtained, which was identical (melting point and infrared spectrum) to the product obtained by the condensation of l-methylpiperazine with 7 - chloro - 1 - ethyl - 4 - oxo - 1,4 - dihydro - quinoline3 - carboxylic acid.
Example 2.
A solution of 4.3 g (0.015 mol) of 6,7 - dichloro - 1 - ethyl - 4 - oxo - 1,4dihydro - quinoline - 3 - carboxylic acid and 9 g of l-methyliperazine in a mixture of methyl Cellosolve (45 cm5) and dimethylformamide (10 cm3) was heated to reflux temperature. After 6 hours, 75% of the theoretical amount of ionized chlorine (1 atom) had been released into the mixture. Heating was continued for a further 2 hours. The solution was concentrated to dryness in vacuo. The residue was taken up in 20 cm3 of ethanol. The solid, which was filtered off and recrystallised from methyl Cellosolve, gave 2.78 g af 6 - chloro - 1 - ethyl - 7 (4 - methylpiperazinyl) - 4 - oxo1,4 - dihydro - quinoline - 3 - carboxylic acid, m.p. 26000, which was identical to the compound described in Example 1.
Example 3.
6 - Chloro - 1 - ethyl - 4 - oxo - 7 - piperazinyl - 1,4 - dihydro - quinoline - 3 carboxylic acid.
2.86 g of 6.7 - dichloro - 1 - ethyl - 4 - oxo - 1,4 - dihydro -, quinoline - 3 carboxylic acid and 10 g of piperazine in 30 cm of dimethylsulphoxide were stirred and heated to 110 C. After two hours, the reaction was complete. After evaporation of the solvent under a good vacuum, the residue was taken up in 20 cm of water.
The solid which precipitated was filtered off and recrystallised from 50 cm of a mixture of ethanol (1 volume) and methyl Cellosolve (1 volume), which enabled an insoluble impurity, which was separated off by filtration of the hot solution to be removed. The crystals, which precipitated on cooling, were filtered off and recrystallised from the same solvent mixture. 1.2 g of 6 - chloro - 1 - ethyl - 4 - oxo7 - piperazinyl - 1,4 - dihydro - quinoline - 3 - carboxylic acid were obtained; m.p.
228-2320C.
Analysis for Cl6Hl8ClN3O,3 (molecular weight 335.8) Calculated % C 57.22 H 5.40 N 12.51 C1 10.56 Found % C 56.99 H 5.57 N 12.64 Cl 10.79 This product was hygroscopic. In a moist atmosphere, it absorbed water and gave a dihydrate which lost its water crystallisation between 100 and 150 C, and then melted at 228-230 C (anhydrous product).
Analysis for C16H18ClN3O3.2H2= (molecular weight 371.8) Calculated % C 51.68 H 5.96 N 11.30 Found % C 51.48 H 5.71 N 11.11 Example 4.
6 - Chloro - 1 - ethyl - 7 - [4 - ( - hydroxyethyl) - piperazinylj - 4 - oxo - 1,4 dihydro - quinoline - 3 - carboxylic acid As described in Example 1, 4.3 g of 6,7 - dichloro 1 - ethyl - 4 - oxo - 1,4dihydro - 3 - quinoline - carboxylic acid and 10.6 g of 1 - (, - hydroxyethyl)piperazine in 45 cm3 of DMSO (dimethylsulphoxide) were heated for 3 hours at 110 C. After evaporation of the solvent under a good vacuum, the viscous residue was taken up in 20 cm of isopropanol; the mixture was stirred and heated under reflux for 20 minutes. After standing for one night at 4 C, the solid was filtered off, washed with ethanol and recrystallised from methyl Cellosolve (15 cm ). 3.5 g of 6 - chloro - 1 - ethyl - 7 [4 - (p - hydroxyethyl) - piperazinyl] - 4 - oxo - 1,4dihydro - quinoline - 3 - carboxylic acid, m.p. 215C, were obtained.
Analysis for Cl8H22CIN3OI (molecular weight 379.5) Calculated % C 56.91 H 5.84 N 11.06 Cl 9.33 Found % C 57.18 H 5.91 N 11.27 Cl 9.18 Example 5.
7 - (4 - Benzylpiperazinyl) - 6 - chloro - 1 - ethyl - 4 - oxo - 1,4 - dihydro quinoline - 3 - carboxylic acid A solution of 4.3 g of 6,7 - dichloro - 1 - ethyl - 4 - oxo - 1,4 - dihydroquinoline - 3 - carboxylic acid and 10.5 g of 1 - benzylpiperazine in 45 cm3 of DMSO was stirred and heated to 11000. After 2 hours, the amount of Cl ions in the reaction mixture corresponded to 94% of the amount calculated for the removal of one halogen atom. After evaporation of the solvent, the reaction product was isolated as in the preceding example; it was purified by recrystallisation from methyl Cellosolve. 3.2 g of 7 - (4 - benzylpiperazinyl) - 6 chloro - 1 - ethyl - 4 - oxo - 1,4 - dihydroquinoline - 3 - carboxylic acid, m.p. 228 C, were obtained.
Analysis for C,3H24ClN,O, (molecular weight 425.9) Calculated % C 64.85 H 5.68 N 9.86 Cl 8.32 Found % C 64.73 H 5.82 N 9.67 Cl 8.39 Example 6.
6 - Chioro - 1 - ethyl - 7 - (4 - formylpiperazinyl) - 4 - oxo - 1,4 - dihydro - 3 quinoline carboxylic acid 4.3 g of 6,7 - dichloro - 1 - ethyl - 4 - oxo - 1,4 - dihydro - quinoline - 3carboxylic acid, 10 g of l-formylpiperazine and 45 cm3 of DMSO were heated for 3 hours at 110-120 C. The reaction product was isolated and purified as in the preceding example. 2 g of 6 - chloro - 1 - ethyl - 7 - (4 - formyl - piperazinyl)4 - oxo - 1,4 - dihydro -quinoline - 3 - carboxylic acid, which melted with decomposition at about 300 C, were obtained Analysis for C17H14ClN3O@, (molecular weight 363.79) Calculated % C 56.12 H 4.98 N 11.55 Cl 9.74 Found % C 56.13 H 5.19 N 11.42 Cl 9.70 Example 7.
6 - Chloro - 1 - ethyl - 7 - morpholino - 4 - oxo - 1,4 - dihydro - quinoline 3 - carboxylic acid 6,7 - Dichloro - 1 - ethyl - 4 - oxo - 1,4 - dihydro - quinoline - 3 - carboxylic acid (4.3 g) and morpholine (10 cm3) in DMSO (45 cm3) were heated for 3 hours at 1100C under the same conditions as in Example 6. The reaction product crystallised on cooling. It was filtered off and recrystallised from 40 cm of a mixture of DMF (dimethylformamide; 1 volume) and methyl Cellosolve (1 volume). 3.3 of 6 - chloro - 1 - ethyl - 7 - morpholino - 4 - oxo - 1,4 - dihydro - quinoline - 3carboxylic acid, m.p. 266"C, were obtained.
Analysis for C,6H1ClN,O4 (molecular weight 336.8) Calculated % C 57.05 H 5.0 & N 8.32 C1 10.52 Found % C 56.82 H 5.31 N 8.39 C1 10.74 Example 8.
6 - Chloro - 1 - ethyl - 4 -oxo - 7 - piperidino - 1,4 - dihydro - quinoline - 3 carboxylic acid A solution of 4.3 g of 6,7 - dichloro - 1 - ethyl - 4 - oxo - 1,4 - dihydroquinoline - 3 - carboxylic acid and 5.5 cm3 of piperidine in a mixture of 20 cm3 of DMF and 20 cm of methyl Cellosolve was heated for 5 hours at 110 C. After concentration of the solution in vacuo, the residue was taken up in 50 cm3 of isopropanol. The solid was filtered off and recrystallised from methyl Cellosolve (50 cm3). 2.4 g of 6 - chloro - 1 - ethyl - 4 - oxo - 7 - piperidino - 1,4 - dihydroquinoline - 3 - carboxyl acid, m.p. 230"C, were obtained.
Analysis for C17H19VlN2O3 (molecular weight 334.8) Calculated % C 60.98 H 5.72 N 8,37 Cl 10.59 Found % C 60.97 H 5.81 N 8.21 Cl 10.79 Example 9.
6 - Chloro - 1 - ethyl - 4 - oxo - 7 - pyrrolidino - 1,4 - dihydro - quinoline 3 - carboxylic acid A mixture of 6,7 - dichloro - 1 - ethyl - 4 - oxo - 1,4 - dihydro - quinoline3 - carboxylic acid (4.3 g), pyrrolidine (10 cm3) and DMSO (45 cm3) was heated for 2 hours at 1100 C. Part of the reaction product precipitated during the reaction.
After cooling, it was filtered off and recrystallised from DMF (50 cm3). 3 g of 6 - chloro - 1 - ethyl - 4 - oxo - 7 - pyrrolidino - 1,4 - dihydro - quinoline - 3carboxylic acid, m.p. 325 C, were obtained.
Analysis for C16H17ClN2O3 (molecular weight 320.8) Calculated % C 59.90 H 5.34 N 8.73 Cl 11.05 Found % C 59.93 H 5.43 N 8.70 Cl 10.90 Example 10.
6 - Chloro - 7 - dimethylamino - 1 - ethyl - 4 - oxo - 1,4 - dihydro quinoline 3 - carboxylic acid 13 g of dimethylamine were dissolved in a mixture of DMF (20 cm3) and methyl Cellosolve (20 cm3). 4.3 g of 6,7 dichloro - 1 - ethyl - 4 - oxo - 1,4dihydro - quinoline - 3 - carboxylic acid were added and the mixture was heated, whilst stirring, in an autoclave at 120-1300C for 7 hours. After cooling, the solution was concentrated to dryness in vacuo and the residue was taken up in 20 cm3 of water. The solid was filtered off and rercystallised from methyl Cellosolve (3 cm3).
3.9 g of 6 - chloro - 7 - dimethylamino - 1 - ethyl - 4 - oxo - 1,4 - dihydroquinoline - 3 - carboxylic acid, m.p. 210"C, were obtained.
Analysis for Q4H1,ClN2O3 (molecular weight 294.7) Calculated % C 57.05 H 5.13 N 9.51 Cl 12.03 Found % C 57.60 H 5.14 N 9.22 Cl 11.82 Example 11.
7 - (4 - Allylpiperazinyl) - 6 - chloro - 1 - ethyl - 4 - oxo 1,4 - dihydro - quinoline 3 - carboxylic acid 2 g of 6,7 - dichloro - 1 - ethyl - 4 - oxo - 1,4 - dihydro - quinoline - 3carboxylic acid, 3.8 g of l-allylpiperazine and 20 cm3 of pyridine were heated under reflux. After 2 hours, dissolution of the acid was complete; after 11 hours, determination of the ionised chlorine (93 /O of theory) showed that the reaction was substantially complete. The solution was concentrated to dryness in vacuo, the residue was taken up in water (20 cm3) and the suspension was brought to pH 7.5 by the addition of acetic acid, whilst stirring. The precipitate was filtered off, washed with water and recrystallised from methyl Cellosolve. 2.05 g of 7 - (4 - allylpiperazinyl) - 6 - chloro 1 - ethyl - 4 - oxo - 1,4 - dihydro - quinoline - 3 - carboxylic acid, m.p. 2120C, were obtained.
Analysis for C,9H22ClN,O, (molecular weight 375.85) Calculated % C 60.71 H 5.90 N 11.18 Cl 9.43 Found % C 60.47 H 5.99 N 11.07 C1 9.29 Example 12.
6 - Chioro - 1 - ethyl - 4 - oxo - 7 - (4 - phenylpiperazinyl) - 1,4 - dihydro quinoline - 3 - carboxylic acid 2.15 g of 6,7 dichloro - 1 - ethyl - 4 - oxo - 1,4 - dihydro - quinoline - 3carboxylic acid, 6.5 g of 1 -phenylpiperazine and 20 cm3 of pyridine were heated under reflux for 16 hours. The solvent was removed in vacuo and the residue was taken up in 20 cm3 of water. The suspension obtained was stirred and brought to pH 7 by the addition of acetic acid. The solid was filtered off and recrystallised from methyl Cellosolve. 1.7 g of 6 - chloro - 1 - ethyl - 4 - oxo - 7 - (4 - phenylpiperazinyl) - 1,4 - dihydro - quinoline - 3 carboxylic acid, m.p. 234-235 C were obtained.
Analysis for C22H22 ClN3O3 (molecular weight = 441.88) Calculated % C 64.15 H 5.38 N 10.20 Cl 8.61 Found % C 63.81 H 5.57 N 9.95 Cl 8.74 Example 13.
17.2 g of 6,7 - dichloro - 1 - ethyl - 4 - oxo - 1, 4- dihydro - quinoline - 3carboxylic acid, 160 cm3 of pyridine and 26 cm3 of l-methylpiperazine were heated under reflux whilst stirring. After 14 hours, the ionised chlorine content of the reaction mixture corresponded to 94% of theory.
The solvent was evaporated off in vacuo, the residue was taken up in 300 cm3 of water, the suspension was stirred, and a solution of acetic acid, which had been diluted to 1/2 strength, was added to the suspension until the pH of the mixture was between 7.5 and 8. The mixture was allowed to stand overnight at 40C. The solid was filtered off, washed with water and
Example 14.
14.3 g of 6,7 - dichloro - 1 - ethyl - 4 - oxo - 1,4 - dihydro - quinoline - 3carboxylic acid, 17.2 g of anhydrous piperazine and 150 cm3 of pyridine were heated under reflux for 6 hours, whilst stirring. After the first quarter of an hour, the solution was homogeneous and then, after about 1 hour 30 minutes, the formation of a precipitate (the hydrochloride of the reaction product) was observed.
After cooling, the mixture was diluted with 80 cm3 of water and the solution was concentrated to dryness in vacuo; the residue was taken up in 100 cm3 of water.
The suspension obtained was stirred and brought to pH 7.5 as indicated in the preceding example. The precipitate was filtered off, washed with water and then recrystallised from a mixture of methyl Cellosolve (1 volume) and ethanol (1 volume).
15 g of 6 - chloro - 1 - ethyl - 4 - oxo - 7 - piperazinyl - 1,4 - dihydro - quinoline3 - carboxylic acid, m.p. 228232 C, were obtained, which was identical to the product of Example 3.
Example 15 6 - Chloro - 1 - methyl - 7 - (4 - methylpiperazinyl) - 4 - oxo - 1,4 - dihydro quinoline - 3 - carboxylic acid 2.18 g of 6,7 - dichloro - 1 - methyl - 4 - oxo - 1,4 - dihydro - quinoline - 3carboxylic acid, 3.5 cm3 of l-methylpiperazine and 25 cm3 of dimethylsulphoxide were heated at 110"C for 3 hours. The solvent was evaporated off in vacuo and the residue was taken up in 100 cm3 of water. The suspension was stirred and mixed with 20 cm3 of N sodium hydroxide solution. The solution obtained, which was slightly turbid, was stirred with animal charcoal and filtered, and then brought to pH 7.5 by the addition of acetic acid. The precipitate was filtered off, washed with water and then recrystallised from methyl Cellosolve. 1 g of 6 - chloro - 1 - methyl7 - (4 - methylpiperazinyl) - 4 - oxo - 1,4 - dihydro - quinoline - 3 - carboxylic acid, m.p. 2860 C, were obtained.
Analysis for C16H18ClN3O, (molecular weight 335.78) Calculated % C 57.22 H 5.40 N 12.51 Found % C 57.51 H 5.98 N 12.65 Example 16.
6 - Chloro - 1 - methyl - 7 - morpholino - 4 - oxo - 1,4 - dihydro - quinoline 3 - carboxylic acid 2.18 g of 6,7 - dichloro - 1 - methyl - 4 - oxo - 1,4 - dihydro - quinoline - 3carboxylic acid, 3 cm3 of morpholine and 34 cm3 of DMSO were heated for 5 hours at 125--131)0C. About 3 hours were required for total dissolution of the dihalogenoacid, and the reaction product then precipitated from the mixture. After returning to room temperature, the mixture was diluted with 30 cm3 of water. The precipitate was filtered off, washed with water and recrystallised from a mixture of DMF (1 volume) and methyl Cellosolve (1 volume). 1.68 g of 6 - chloro - 1 - methyl - 7 - morpholino4 - oxo - 1,4 - dihydro - quinoline - 3 - carboxylic acid were obtained; m.p. 334"C.
Analysis for CtsHlsclN2O4 (molecular weight 322.74) Calculated % C 55.82 H 4.68 N 8.68 Found % C 55.72 H 4.65 N 8.35 Example 17.
6 - Chloro - 1 - methyl - 4 - oxo - 7 - piperazinyl - 1,4 - dihydro - quinoline 3 - carboxylic acid.
2.45 g of 6,7 - dichloro - 1 - methyl - 4 - oxo - 1,4 - dihydro - quinoline - 3carboxylic acid, 3.1 g of piperazine and 30 cm3 of pyridine were heated under reflux for 8 hours. The dihalogen-acid went rapidly into solution; after 5 hours, a precipitate appeared which consisted principally of the hydrochloride of the reaction product.
The solvent was evaporated off, the residue was taken up in 100 cm3 of water, and 20 cm3 of N sodium hydroxide solution were then added to the mixture. The solution, which was slightly turbid, was brought to pH 7.5, by the addition of acetic acid. The precipitate was filtered off and suspended in 100 cm3 of water; the addition of 10 cm3 of N HCI led to almost total dissolution. A slight amount of insoluble material was removed by filtration. The solution was brought to pH 7.5 by the addition of N NaOH. The solid was filtered off and recrystallised from a mixture of DMF (1 volume) and methyl Cellosolve (2 volumes). 1.32 g of 6 - chloro - 1 - methyl ~ 4 oxo - 7 - piperazinyl - 1,4 - dihydro - quinoline - 3 - carboxylic acid, m.p. 2880C, were obtained.
Analysis for ClsHl,;CIN303 (molecular weight 321.76) Calculated % C 55.98 H 5.01 N 13.06 Found % C 56.04 H 5.22 N 12.80 Example 18.
6 - Bromo - 1 - ethyl - 7 - (4 - methylpiperazinyl) - 4 - oxo - 1,4 - dihydro- quinoline - 3 - carboxylic acid. a) 3.3 g of 6 - bromo - 7 - chloro - 1 - ethyl - 4 - oxo - 1,4 - dihydroquinoline -3- carboxylic acid (0.01 mol) and 4.5 cm3 of l-methylpiperazine (0.04 mol), in solution in 30 cm3 of dimethylsulphoxide, were heated at 1100C for 4 hours.
After cooling, the solution was diluted with 250 cm5 of water. The precipitate formed was filtered off, washed with water and recrystallised from 50 cm3 of methyl Cellosolve. 1.3 g of 6 - bromo - 1 - ethyl - 7 - (4 - methylpiperazinyl) - 4 - oxo - 1,4dihydro - quinoline - 3 - carboxylic acid, m.p. 2090C (decomposition), were obtained.
Analysis for C17H,BrNiO, (molecular weight = 394.26) Calculated % C 51.78 H 5.11 N 10.65 Br 20.26 Found % C 51.72 H 5.36 N 10.56 Br 20.24 6 Bromo - 7 - chloro - 1 - ethyl - 4 - oxo - 1,4 - dihydro - quinoline - 3carboxylic acid was prepared from 3 - chloro - 4 - bromoaniline bv a known process as follows: 23 g of 3 - chloro - 4 - bromoaniline and 23 g of ethyl ethoxymethyl enemalonate were heated at 1100 in a round-bottomed flask equipped with a descending condenser which enabled the alcohol formed in the reaction to be collected. The reaction ended after heating for 2 hours. After cooling1 the solid was recrystallised from cyclohexane. 33 g (yield 88%) of ethyl 3 - chloro - 4- bromoanilinomethylene malonate. m.n. 8687 C, were obtained.
33 g of the above compound were added to 50 cm3 of Dowtherm (Trade Mark), heated at 2500C and stirred in a round-bottomed flask equipped with a descending condenser which enabled the alcohol formed in the reaction to be collected: the reaction was comnlete after heating for 15 minutes. After cooling, the contents of the roundbottomed flask were taken up in 200 cm3 of ethyl acetate. The solid was separated and recrystallised from dimethylformamide. 27.9 g of 6 - bromo - 7 - chloro - 3ethoxycarbonyl - 4 - hydroxy - quinoline, m.p. 368-3700C (decomposition), were obtained. 13 g of 6 - bromo - 7 - chloro - 3 - ethoxycarbonyl - 4 - hydroxyquinoline, 11 g of potassium carbonate and 100 cm3 of dimethylformamide were heated at 1 100C for 1 hour, whilst stirring. After cooling to 800 C, 16 cm3 of ethyl iodide were added to the mixture which was stirred and heated at 1 100C for 4 hours. After concentration to dryness in vacuo, the residue was taken up in 200 cm3 of water. The mixture was extracted with chloroform (3 X 100 cm3), and the combined organic extracts were washed with water, dried (MgSO4) and concentrated to dryness. The residue, recrystallised from 95 cm3 of isopropanol, gave 10 g of 6 - bromo - 7 - chloro1 - ethyl - 4 - oxo - 1,4 - dihydro - 3 - ethoxycarbonyl - quinoline, m.p. 166"C.
10 g of the above ester were added to an aqueous-alcoholic solution of sodium hydroxide (NaOH: 2.25 g, water: 50 cm3, ethanol: 100 cm3). The mixture was heated under reflux for 30 minutes. The solution was concentrated to dryness in vacuo. The residue was suspended in 100 cm3 of water. The solution was acidified by adding 3.4 cm3 of acetic acid. The solid was separated and recrystallised from DMF (90 cm3).
8.1 g (89%) of 6 - bromo - 7 - chloro - 1 - ethyl - 4 - oxo - 1,4 - dihydro - quinoline3 - carboxylic acid, m.p. 320"C (decomposition), were obtained.
Example 19.
6 - Bromo - 1 - ethyl - 7 - morpholino - 4 - oxo 1,4 - dihydro - quinoline - 3 carboxylic acid.
3.3 g of 6 - bromo - 7 - chloro - 1 - ethyl - 4 - oxo - 1,4 - dihydro - quinoline3 - carboxylic acid and 3.5 g of morpholine, in solution in 30 cm3 of DMSO, were heated at 1100C for 6 hours.
After cooling, the mixture was diluted with 200 cm3 of water. The precipitate was filtered off, washed with water and recrystallised from methyl Cellosolve (50 cm3). 2.4 g (yield 63%) of 6 - bromo - 1 - ethyl - 7 - morpholino - 4 - oxo - 1,4dihydro - quinoline - 3 - carboxylic acid, m.p. 2660 C, were obtained.
Analysis for C,,H,?BrN,O, (molecular weight 380.5) Calculated % C 50.50 H 4.50 N 7.36 Found % C 50.38 H 4.68 N 7.09 Example 20.
1 - Ethyl - 6 - fluoro - 7- (4 - methylpiperazinyl) - 4 - oxo - 1,4 - dihydro quinoline - 3 - carboxylic acid 113 g (0.42 mol) of 7 - chloro - 6 - fluoro - 1 - ethyl - 4 - oxo - 1,4dihydro - quinoline - 3 -carboxylic acid, 170 g (1.68 mol) of 1 - methylpiperazine and 600 cm3 of DMSO were stirred and heated at 1 100C for 7 hours 30 minutes.
The solvent was removed by distillation in vacuo. The residue was taken up in 1,300 cm3 of 10% aqueous acetic acid. The mixture was stirred and heated at 60"C.
The solution, which was slightly turbid, was treated with 10 g of animal charcoal and stirred at the same temperature for half an hour. After filtration and cooling, the solution was brought to pH 7.5 by the addition of 5N NaOH, whilst stirring vigorously. After standing for one night at 40C, the precipitate was filtered off, washed with water and dried. The crude product (85 g) was recrystallized from 500 cm3 of DMF. 80 g of 1 - ethyl - 6 - fluoro - 7 - (4 - methylpiperazinyl) - 4 - oxo - 1,4dihydro - quinoline - 3 - carboxylic acid, m.p. 270--272"C (decomposition) were obtained.
Analysis for C17H2oFN?109 (molecular weight 333.35) Calculated % C 61.26 H 6.00 N 12.61 Found % C 60.94 H 5.93 N 12.75 7 - Chloro - 6 - fluoro - 1 - ethyl - 4 - oxo - 1,4 - dihydro - quinoline - 3carboxylic acid, used as the starting material, was prepared as follows: 165 g of 3chloro - 4 - fluoroaniline and 254 g of ethyl ethoxymethylenemalonate were stirred and heated at 1300 C. The alcohol formed during the reaction was collected by distillation. The reaction was complete afer 1 hour 30 minutes. The reaction product, m.p. 68 69 C, crystallised on cooling. 119 g of ethyl 3 - chloro - 4 - fluoroanilinomethylenemalonate, in solution at 100 C in 200 cm3 of Dowtherm, were added to 200 cm3 of the same solvent, stirred vigorously and heated at 2500C in a roundbottomed flask equipped with a descending condenser. After the addition, this temperature and the stirring were maintained until the alcohol formed in the reaction had finished distilling, which required about 45 minutes. After cooling, the precipitate formed was filtered off, washed with acetone and dried in air, and 91 g of 2 - chloro3 - ethoxycarbonyl - 6 - fluoro - 4 - hydroxyquinoline, m.p. 335"C (decomposition), were obtained. 80.85 g of the above ester, 500 cm8 of dimethylformamide and 82.8 g of potassium carbonate were heated at 1100C for one hour, whilst stirring, in a roundXbottomed flask equipped with a reflux condenser. During this time, the starting material dissolved. After cooling to 600 C, 187 g of ethyl iodide were added, whilst still stirring vigorously. The mixture was stirred and heated at llO"C until the solution was virtually neutral to indicator paper, which required from 5 to 6 hours. After concentration in vacuo, the residue was taken up in 250 cm3 of water and the mixture was extracted with chloroform (2 X 300 cm3). lhe combined organic extracts were washed with water, dried (MgSO4) and then concentrated to dryness in vacuo.
The residue was recrystallised from isopropanol (100 cm3). 83 g of 7 - chloro - 3ethoxycarbonyl - 1 - ethyl - 6 - fluoro - 4 - oxo - 1,4 - dihydroquinoline were obtained, which melts in two stages: m.p. 1450C, solidification, followed by m.p.
1620C.
113 g of this ester were saponified by heating under reflux for 1 hour 30 minutes with an aqueous-alcoholic solution of sodium hydroxide (NaOH: 30 g, water: 300 cm3, ethanol: 100 cm3). At the end of the alkaline treatment, the solution was treated with 10 g of animal charcoal, filtered and neutralised by adding 46 cm3 of acetic acid.
The precipitate was filtered off, washed with water and recrystallised from DMF (550 cm3). 95 g of 7 - chloro - 6 - fluoro - 1 - ethyl - 4 - oxo - 1,4 - dihydroquinoline - 3 - carboxylic acid, m.p. 277"C, were obtained.
Example 21.
53.9 g of 7 - chloro - 6 - fluoro - 1 - ethyl - 4 - oxo - 1,4 - dihydro - quinoline3 - carboxylic acid and 80 g of 1 - methylpiperazine in suspension in 300 cm5 of pyridine, were heated under reflux for 16 hours, whilst stirring. After heating for about one hour, the acid dissolved and the reaction product began to precipitate partially after the second hour. After 14 hours, 93% of the theoretical amount of chlorine was in the ionised form.
After cooling, 250 cm3 of water were added to the mixture and the latter was then concentrated to dryness in vacuo (15 mm Hg at 100"C), in order to remove the pyridine and the excess of methylpiperazine as completely as possible. The residue was taken up in 800 cm3 of water and the mixture was stirred vigorously and treated with acetic acid (55 cm3) in order to dissolve the solid portion. The solution, which was slightly turbid, was treated with 5 g of animal charcoal, stirred for 30 minutes, filtered and then brought to pH 7 by adding 5N NaOH. After standing overnight at 4"C, the precipitate was filtered off and washed with water and with alcohol. 43.7 g of 1 - ethyl - 6 - fluoro - 7 - (4 - methylpiperazinyl) - 4 - oxo - 1,4 - dihydroquinoline - 3 - carboxylic acid, m.p. 2700 C, which was identical to the product of Example 20, were obtained.
Methanesuiphonate 3.33 g of the acid (0.01 mol) were suspended in 50 cm3 of ethanol, the mixture was heated under reflux and 1 g (0.011 mol) of methanesulphonic acid was added thereto. The starting material dissolved and the salt then precipitated. After 5 minutes, the mixture was cooled to OOC and the solid was separated and then recrystallised from methanol, 3.8 g of the methanesulphonate, m.p. 28X286 C (decomposition), were obtained.
Analysis for C17H20FN3O3.HO3SCH3 (molecular weight 429) Calculated % C 50.03 H 5.63 N 9.78 S 7.45 Found % C 50A9 H 6.04 N 9.55 S 7.39 Example 22.
7 - (4 - Allylpiperazinyl) - 1 - ethyl - 6 - fluoro - 4 - oxo - 1,4 - dihydro quinoline - 3 - carboxylic acid 27 g (0.1 mol) ofd 7 - chloro - 1 ethyl - 65 fluoro - 4 - oxo - 1,4 - dihydroquinoline - 3 - carboxylic acid, 50 g of 1 - allylpiperazine (0.4 mol) and 150 cm of DMSO were stirred and heated at 110 C for 8 hours, during which the reaction product partially precipitated.
After cooling, the mass was taken up in 300 cm3 of water; the precipitate was filtered off, washed with water and recrystallised from 220 cm3 of methyl Cellosolve.
20.5 g of 7 - (4 - allylpiperazinyl) - 1 - ethyl - 6 - fluoro - 4 - oxo - 1,4dihydro - quinoline - 3 - carboxylic acid, m.p. = 2360 C, were obtained.
Analysis for C1,H,2FN3d, (molecular weight 359) Calculated % C 63.50 H 6.13 N 11.69 Found % C 63.83 H 6.22 N 11.12 Using the procedures described in Examples 21 and 22, other new compounds have been obtained, the physical constants of which are indicated in Table 1 which follows.
TABLE 1
0 Example No. R R N M.P. C Solvent and reaction time 23 N- 259-260 a) pyridine (14 hours) 24 H5C6-C}f2-N N- 214 b) DMS0 (8 hours) mm 25 HOH2C-CH -N N- 230 c) DMS0 (8 hours) 26 D X 348-350 d) DMS0 (8 hours) 27 zHO 206 d) DMS0 (8 hours) H0 28 < \ ) 215 d), pyridine (9 hours) 29 QHGN U 285-287 c) DIMS0 (8 hours) Recrystallisation solvents: a) DMF; b) Ethanol (10 volumes)-DMF (1 volume); c) Ethanol (10 volumes)-DMF (1 volume); d) Ethanol.
Example 30.
6 - Flouro - 1 - methyl - 7 - (4 - methylpiperazinyl) - 4 - oxo - 1, 4 - dihydro 3 - carboxylic acid 2.55 g (0.01 mol) of 7 - chloro - 6 - fluoro - 1 - methyl - 4 - oxo - 1,4dihydro - quinoline - 3 - carboxylic acid, 4.5 cm3 of 1-methylpiDerazine (0.011 mol) and 32 cm3 of DMSO were heated at 1100C for 4 hours. After cooling, the mixture was taken uo in 150 cm3 of water. The crystalline precipitate was filtered off, washed and recrystallised from 100 cm3 of methyl Cellosolve. 1.3 g of 6 - fluoro - 1methyl - 7 - (4 - methylpiperazinyl) - 4 - oxo - 1,4 - dihydro - quinoline - 3 carboxylic acid, m.p. 3040C (decomposition), were obtained.
Analysis for C16H18FN3O3 (molecular weight 319.32) Calculated % C 60.18 H 5.68 N 13.16 Found % C 60.58 H 5.85 N 12.99 The 7 - chloro - 6 - fluoro - 1 - methyl - 4 - oxo - 1,4 - dihydro - quinoline3 - carboxylic acid used for this synthesis was obtained from the 7 - chloro - 3ethoxycarbonyl - 6 - fluoro - quinoline described in Example 20.
14 g of 7 - chloro - 3 - ethoxyca1tonyl - 6 - fluoroquinoline, 14 g of potassium carbonate and 180 cm3 of DMF were stirred and heated at llO"C for one hour in a round-bottomed flask equipped with a reflux condenser. After cooling to 500C, 30 cm3 of methyl iodide were added dropwise. The mixture was stirred and heated at 7080 C until the medium was neutral, which required about 8 hours.
After concentration to dryness in vacuo, the residue was taken up in 100 cm3 of water. The mixture was extracted with chloroform (3 X 50 cm3) and the combined organic extracts were dried (MgSO,) and concentrated to dryness in vacuo.
The residue was recrystallised from ethanol (200 cm3). 13.5 g of 7 - chloro - 3ethoxy - carbonyl - 6 - fluoro - 1 - methyl - 4 - oxo - 1,4 - dihydroquinoline, m.p.
2200 C, were obtained.
5 g of this ester were saponified by heating under reflux for 30 minutes with an aqueous-alcoholic solution of sodium hydroxide (NaOH: 1.4 g, water: 50 cm3, ethanol: 50 cm3). The solution was neutralised with acetic acid (2 cm3). The precipitate was filtered off, washed with water and recrystallised from DMF (55 cm3) 4.05 g of 7 - chloro - 6 - fluoro - 1 - methyl - 4 - oxo - 1,4 - dihydro - quinoline - 3 carboxylic acid, m.p. 3420 C, were obtained.
Example 31.
6 - Fluoro - 1 - methyl - 4 - oxo - 7 - piperazinyl - 1, 4- dihydro - quinoline 3 - carboxylic acid 2.55 g (0.01 mol) of 7 - chloro - 6 - fluoro - 1 - methyl - 4 - oxo - 1,4dihydro - quinoline - 3 - carboxylic acid and 3.5 g (0.04 mol) of piperazine in 34 cm3 of pyridine were heated under reflux for 7 hours, whilst stirring. The starting materials had completely dissolved in 2 hours and the reaction product began to precipitate in the medium after 4 hours.
The solvent was removed by distillation in vacuo (15 mm Hg) at 1000 C. The residue was suspended in 30 cm3 of water and the mixture was stirred vigorously and its pH was brought to 7.5 by gradually adding acetic acid.
The solid was filtered off, washed with water and recrystallised from a mixture of DMF (2 volumes) and ethanol (1 volume). 1.5 g of 6 - fluoro - 1 - methyl - 4oxo - 7 - piperazinyl - 1,4 - dihydro - quinoline - 3 - carboxylic acid, m.p. 310 C with decomposition, were obtained.
Analysis for ClsHj6PN3OI3 (molecular weight 305.3) Calculated % C 59.00 H 5.28 N 13.78 Found % C 58.44 H 5.54 N 13.43 Example 32.
6 - Fluoro - 1 - methyl - 7 - morpholino - 4 - oxo - 1,4 - dihydro - quinoline 3 - carboxylic acid 2.55 g (0.01 mol) of 7 - chloro - 6 - fluoro - 1 - methyl - 4 - oxo - 1, 4- dihydroquinoline - 3 - carboxylic acid, 3.5 cm3 of morpholine (0.01 mol) and 34 cm3 of DMSO were heated at 110 C for 7 hours, whilst stirring. The reaction product precipitated after heating for 5 hours. After cooling, the mixture was diluted with water (100 cm3) and the solid was filtered off, washed with water and recrystallised from DMF (45 cm3). 1 g of 6 - fluoro - 1 - methyl - 7 - morpholino - 4 - oxo - 1,4dihydro - quinoline - 3 - carboxylic acid, m.p. 3 160C (decomposition), was obtained.
Analysis for C,,H1,FN20 (n:olecular weight 306.3) Calculated % C 58.78 H 4.93 N 9.14 Found % C 58.42 H 5.17 N 9.29 Example 33.
1 - Allyl - 6 - fluoro - 7 - (4 - methylpiperazinyl) - 4 - oxo - 1,4 - dihydro quinoline - 3 - carboxylic acid 1.4 g of 1 - allyl - 7 - chloro - 6 - fluoro - 4 - oxo - 1,4- dihydro - quinoline3 - carboxylic acid(0.005 mol), 2.5 cm3 of pyridine were heated under reflux for 20 hours. The solvent was driven off in vacuo (15 mm Hg) at 1000 C. The residue was taken up in 25 cm of water and the suspension was stirred and its pH was brought to 7.5 by adding acetic acid. The mixture was extracted with chloroform ( 4 X 10 cm ), the combined organic extracts were dried (MgSO4) and evaporated to dryness and the residue was recrystallised from 10 cm3 of isopropanol.
1 g of 1 - allyl - 6 - fluoro - 7 - (4 - methylpiperazinyl) - 4 - oxo - 1,4dihydro - quinoline - 3 - carboxylic acid, m.p. 208"C, was obtained.
Analysis for ClsH2oFN*303 (molecular weight 345.36) Calculated % C 62.59 H 5.84 N 12.17 Found % C 62.28 H 6.00 N 12.15 The 1 - allyl - 7 - chloro - 6 - fluoro - 4 - oxo - 1,4 - dihydro - quinoline - 3carboxylic acid used in this example, and in those which follow, was prepared from 7- chloro - 3 - ethoxy - carbonyl - 6 - fluoro - 4 - hydroxyquinoline: 13.5 g of 7 - chloro - 3 - ethoxycarbonyl - 6 - fluoro - 4 - hydroxy - quinoline and 13.8 of potassium carbonate in 160 cm of DMF were stirred and heated at 110 C for 1 hour in a round-bottomed flask equipped with a reflux condenser. After cooling to 60 C, the solution was treated with 24 g of allyl bromide. The mixture was stirred and heated at 100 C until the medium was neutral (duration: about 6 hours). The solvent was evaporated off in vacuo, the residue was taken up in 300 cm3 of water and the reaction product was extracted with chloroform (3 X 100 cm3).
The combined organic extracts were washed with water, dried (MgSO4) and evaporated to dryness. The residue was recrystallised from 72 cm3 of isopropanol.
12 g of 1 - allyl - 7 - chloro - 3 - chloro - 3 - ethoxycarbonyl - 6 - fluoro - 4 - oxo - 1,4dihydroquinoline, m.p. = 162-164 C, were obtained.
9 g of this ester werre saponified by heating under reflux for one hour with an aqueous-alcoholic solution of sodium hydroxide (NaOH: 2.9 g, water: 40 cm3, ethaool: 70 cm3). Whilst still hot, the solution was acidified with acetic acid (2.9 cm3). After cooling, the solid was filtered off, washed with water and recrystallised from 40 cm3 of a mixture of DMF (1 volume) and ethanol (1 volume).
6.5 g of 1 - allyl - 7 - chloro - 6 - fluoro - 4 - oxo - 1,4 - dihydro - quinoline3 - carboxylic acid, m.p. 234"C, were obtained.
Example 34.
1 - Allyl - 6 - fluoro - 4 - oxo - 7 - piperazinyl - 1,4 - dihydro - quinoline 3 - carboxylic acid A mixture of 1 - allyl - 7 - chloro - 6 - fluoro - 4 - oxo - 1,4 - dihydro - quinoline3 - carboxylic acid (2.8 g; 0.01 mol), piperazine (3.5 g; 0.04 mol) and pyridine (20 cm3) was heated under reflux for 20 hours. The solvent was evaporated off in vacuo (15 mm Hg) while heating to 10C C and the residue was taken up in 30 cm3 of water.
The alkaline suspension (pH = 9.4) was stirred and adjusted to pH 7.3 by adding acetic acid.
The solid was filtered off and recrystallised from 40 cm3 of a mixture of DMF (1 volume) and ethanol (5 volumes). 1,4 g of 1 - allyl - 6 - fluoro - 4 - oxo - 7piperazinyl - 1,4 - dihydro - quinoline - 3 - carboxylic acid, m.p. 1360 C, were obtained, which, in air, fixes one molecule of water (hydrate, m.p. 1420C).
Analysis for C17H18FN3O3.H2O (molecular weight 349.3) Calculated % C 58.44 H 5.56 N 12.03 Found % C 58.41 C 5.56 N 12.45 Example 35.
1 - Allyl - 6 - fluoro - 7 - [4 - (P - hydroxyethyl) - piperazinylj - 4 - oxo - 1,4 dihydro - quinoline - 3 - carboxylic acid.
This acid was obtained by the procedure described in Example 35, but replacing the piperazine with the equivalent amount of 1 - (8 - hydroxyethyl) - piperazine (5.2 cm3). The crude product was recrystallised from 20 cm of isopropanol- and had a m.p. of 171 C. Yield 1.5 g.
Analysis for C1,H22FNaO4 (molecular weight 75.38) Calculated % C 60.80 H 6.18 N 11.13 Found % C 60.92 H 6.15 N 10.97 Example 36.
1 - Allyl - 7 - (4 - allylpiperazinyl) - 6 - fluoro - 4 - oxo - 1,4 - dihydro - quinoline, 3 - carboxylic acid This acid was prepared by the procedure of Example 35, but replacing the piperazine with the equivalent amount (6.05 g) of l-allylpiperazine. The crude product was recrystallised from ethanol (20 cm3). Yield: 1.5 g, m.p. 1860C.
Analysis for C20H22FNaO3 (molecular weight 371) Calculated % C 64.67 H 5.96 N 11.15 Found % C 64.90 H 6.14 N 11.28 Example 37.
1 - Allyl - 7 - (4 - benzylpiperazinyl) - 6 - fluoro - 4 - oxo - 1,4 - dihydro quinoline - 3 - carboxylic acid 2.8 g (0.01 mol) of 1 - allyl - 7 - chloro - 6 - fluoro - 4 - oxo - 1,4 - dihydroquinoline - 3 carboxylic acid, 7.2 g (0.04 mol) of 4-benzylpiperazine and 15 cm of DMSO were stirred and heated at 110 C for 6 hours. The solvent was removed by distillation in vacuo. The residue was taken up in 40 cm3 of water. The suspension was adjusted to pH 7.3 by adding acetic acid. The precipitate was extracted with chloroform (4 X 20 cm3). The combined organic extracts were washed with water and then evaporated to dryness to give a viscous residue which crystallised on mixing with 10 cm3 of isopropanol. The solid was separated and recrystallised from methyl Cellosolve (30 cm3). 1.5 g ethanol: 50 cm3). The salt which had partially precipitated was dissolved by adding 150 cm3 of water. The solution was treated with 6 cm3 of acetic acid.
The precipitate was filtered off, washed with water and recrystallised from 170 cm3 of methyl Cellosolve. 15.4 g of 1 - benzyl - 7 - chloro - 6 - fluoro - 4 - oxo1,4 - dihydro - quinoline - 3 - carboxylic acid, m.p. 2500 C, were obtained.
Example 40.
6 - fluoro - 7 - (4 - methyl - piperazinyl) - 4 - oxo - 1 - vinyl - 1,4 - dihydro quinoline - 3 - carboxylic acid (Process A) A solution of 1.3 g of 7 - chloro - 6 - fluoro - 4 - oxo - 1 - vinyl - 1,4 - dihydroquinoline - 3 - carboxylic acid and 2.5 cm3 of 1 - methyl - piperazine in 13 cm3 of pyridine was heated for 17 hours under reflux. The reaction mixture was concentrated to dryness under reduced pressure and the residue was taken up in 10 cm3 of N NaOH. The solution obtained, which had a deep brown colour, was heated and agitated with animal charcoal (0.5 g). After filtration, the pH of the solution was adjusted to 7 by the addition of acetic acid, then extracted with chloroform (4 X 10 cm3). The combined organic extracts were evaporated to dryness and the residue was recrystallised from ethanol. The product, 6 - fluoro - 7 - (4 - methylpiperazinyl) - 4 - oxo - 1 - vinyl - 1,4 - dihydro - quinoline - 3 - carboxylic acid, had m.p. 2420 C.
Analysis for C,,H,,FNDO, (molecular weight 331.3) Calculated % C 61.59 H 5.47 N 12.68 Found % C 61.38 H 5.66 N 12.51 The starting material for this process, 7 - chloro - 6 - fluoro - 4 - oxo - 1 - vinyl 1,4 - dihydro - quinoline - 3 - carboxylic acid, was obtained as follows: A solution of 8.1 g of 7 - chloro - 3 - ethoxycarbonyl - 6 - fluoro - 4 - oxo1,4 - dihydro - quinoline and 8.2 g of potassium carbonate in 70 cm3 of DMF was agitated and heated at llO"C for 1 hour. After cooling to 600 C, 15 g of 2-bromoethanol were added to the reaction mixture and it was agitated and heated at llO"C for 4 hours. After evaporation of the solvent under reduced pressure, 100 cm3 of water were added to the residue and the aqueous mixture was extracted with chloroform (4 X 100 cm5). The combined organic extracts were washed with water (2 X 100 cm3), dried over Na2SO,, filtered and then evaporated to dryness. The residue was recrystallised from ethanol (150 cm3). 6.75 g of 7 - chloro - 6 - fluoro - 3 - ethoxycarbonyl - 1 - (2 - hydroxyethyl) - 4 - oxo - 1,4 - dihydro - quinoline, m.p. 202"C, were obtained; yield 67%.
27 g of the foregoing ester product were added, portionwise, to an agitated and cooled solution of pyridine (8.1 cm3) in thionyl chloride (54 cm3). The addition was carried out at such a rate that the temperature of the mixture remained between 0 and 5 C. After returning to room temperature, the solution was heated for 1 hour under reflux and the excess of reagent was then removed by distillation under reduced pressure. The residue was added, with agitation, to 100 cm3 of iced water. The suspension obtained was neutralised by the addition of 10% aqueous Na2CO3. The precipitate obtained was filtered off, washed with water and recrystallised from ethanol (480 cm3). 22.4 g of 7 - chloro - 1 - (2 - chloroethyl) - 3 - ethoxycarbonyl - 6fluoro - oxo - 1,4 - dihydro - quinoline, m.p. 222"C, were obtained, yield 80%.
5.9 g of this ester product were added to an aqueous alcoholic solution of caustic soda (8.5 g NaOH, 80 cm3 water, 30 cm3 ethanol). The mixture was heated for 2 hours under refiux. After dissolution of the ester, the sodium salt of the product formed was precipitated. It was dissolved by the addition of water (50 cm3) while maintaining reflux temperature. The solution was acidified with hydrochloric acid, the precipitate obtained was filtered off and washed with water and then with ethanol.
4.8 g of 7 - chloro - 6 - fluoro - 4 - oxo - 1 - vinyl - 1,4 - dihydro - quinoline3 - carboxylic acid, m.p. 210 C, were obtained.
Example 41.
6 - Fluoro - 7 - morpholino - 4 - oxo - 1 vinyl - 1,4 - dihydro - quinoline 3 - carboxylic acid 2.6 g of 7 - chloro - 6 - fluoro - 4 - oxo - 1 - vinyl - 1,4 - dihydro - quinoline3 -carboxylic acid, 3.5 cm3 of morpholine and 30 cm3 of dimethylsulphoxide were heated for 15 hours under reflux.. The solvent was removed by distillation under reduced pressure and the residue was taken up in 20 cm of ethanol. The insoluble solid was separated and recrystallised from 8 cm3 of a 1:1 (by volume) mixture of methyl Cellosolve and ethanol. 0.4 g of 6 - fluoro - 7 - morpholino - 4 - oxo1 - vinyl - 1,4 - dihydroquinoline - 3 - carboxylic acid, m.p. 218-220 C, was obtained.
Analysis for C1H15FN2O4 (molecular weight 318.29) Calculated % C 60.37 H 4.75 N 8.79 Found % C 60.37 H 4.98 N 8.62 Example 42.
6 - Fluoro - 7 - (4 - methyl - piperazinyl) - 4 - oxo - 1 - vinyl - 1,4 - dihydro quinoline - 3 - carboxylic acid. Process B. a) 28 g of 7 - chloro - 6 - fluoro - 1 - (2 - hydroxyethyl) - 4 - oxo - 1,4dihydro - quinoline - 3 - carboxylic acid, 40 g of l-methyl-piperazine and 200 cm3 of pvridine were heated for 18 hours under reflux. The solvent was removed by distillation under reduced pressure. The residue was taken up in 100 cm9 of water, the mixture was agitated and adjusted to pH 6.8 by the addition of acetic acid. The solid was filtered off, washed with water and recrystallised from DMF. 24 g of 6fluoro - 1 - (2 - hydroxyethyl) - 7 - (4 - methyl - piperazinyl) - 4 - oxo - 1,4dihydro - quinoline - 3 - carboxylic acid, m.p. 2700 C, were obtained.
Analysis for C17H2FN,sOs (molecular weight 349.35) Calculated % C 58.44 H 5.76 N 12.02 Found % C 58.58 H 5.95 N 11.91 b) 8.75 g (0.025 mole) of the preceding acid were added, in small portions, to 75 cm of thionyl chloride while the latter was agitated and externally cooled. The addition was carried out at such a rate that the temperature of the mixture was maintained between 0 and 5 C. 2 cm3 (0.0125 mole) of pyridine were then added.
After returning to room temperature, the mixture was heated under reflux for 5 hours.
The excess of thionyl chloride was removed bv evaporation under reduced pressure.
The residue was added to 60 cm3 of ethanol. The solution obtained was agitated for 15 minutes at room temperature. The solvent was evaporated under reduced pressure and the residue was taken un in 100 cm9 of water. The mixture was agitated and adjusted to pH 7 by the addition of 10% aqueous Na2COI3 solution. The precip;tate was filtered off, washed with iced water and dried under reduced pressure. 7 g of 1 (2 - chloroethyl) - 3 - ethoxycarbonyl - 6 - fluoro - 7 - (4 - methyl - piperazinyl)4 - oxo - 1,4 - dihydro - quinoline were obtained; yield 70%. The product was purified by recrystallisation from 80 cm3 of a 1:1 (by volume) mixture of ethanol and isopropyl oxide; m.p. 208 C.
In damp air, this ester forms a hydrate containing + molecule of water.
Analysis for CloH2gCIFN3Oa . + H,O (molecular weight 404.86) Calculated % C 56.38 H 5.93 N 10.38 Found % C 55.95 H 5.69 N 10.02 c) 6 g of the ester product of b) were added to an aqueous alcoholic solution of caustic soda (6.5 g NaOH, 45 cm3 water, 25 cm ethanol). The mixture was heated under reflux for 2 hours; the sodium salt of the reaction product partially precipitated. The solvents were eliminated under reduced pressure. The residue was taken up in 50 cm3 of water. The suspension was vigorously agitated and adjusted to pH 6.8 by the addition of acetic acid. After standing overnight at 40C, the solid which had precipitated was filtered off, washed with iced water and dried over phosphoric anhydride under reduced pressure. 4 g of 6 - fluoro - 7 - (4 - methylpiperazinyl) - 4 - oxo - 1 - vinyl - 1,4 - dihydro - quinoline - 3 - carboxylic acid were obtained: yield 80%. The product was purified by recrystallisation from 100 cm of methyl Cellosolve; m.p. 2420 C, identical to the product described in Example 21.
The antimicrobial activity of the compounds according to the invention has been investigated in vitro on Gram positive and Gram negative bacteria using, as the culture medium, nutrient agar (N.A.) of the following formulation: meat extract 3 g peptone 5 g agar 15 g water q.s.p. 1,000 cm3 After sterilisation at 1200 C, the pH was 6.8.
The minimum inhibitory concentrations (M.I.C.) were determined bv dilution of the test compounds in this mixture, the concentration ranging from 0.05 to 100 Sag/cm3 in a geometric progression with a factor of 2.
The inoculation of the dishes was carried out by means of a multiple inoculator with 10-3 dilutions of 18 hour old broth cultures.
The dishes were placed in an oven at 37"C and the readings were taken after an incubation time of 18 hours. The M.I.C. was taken as the lowest concentration which inhibited a culture.
Table 2 gives the M.I.C. of the compounds of the invention containing a chlorine atom in the 6-position against 5 Gram positive bacteria (from 1 to 5) and 17 Gram negative bacteria (from 6 to 22).
The activities of the corresponding acids which do not contain a halogen substituent in the 6-position are also shown, for purpose of comparison, for certain of the compounds studied, especially those of Examples 1 and 4. These comparison compounds are denoted T. and T. respectively.
Examination of Table 2 shows the importance of the chlorine atom in the activity of the compounds of the invention and the superiority of the latter over their nonhalogenated homologues.
The following compounds are specially singled out, because of their broad spectrum of activity, as being useful for therapeutic applications in human or veterinary medicine: Example 1 - 6 - chioro - 1 - ethyl - 7 - (4 - methylpiperazinyl) - 4 - oxo 1,4 - dihydro - quinoline - 3 - carboxylic acid.
Example 2 - 6 - chloro - 1 - ethyl - 4 - oxo - 7 - piperazinyl - 1,4 - dihydro quinoline - 3 - carboxylic acid.
TABLE 2 (M.I.C. in g/cm )
Ex. 1 T1 Ex. 3 Ex. 4 T4 Ex. 5 Ex. 7 1 Staph. 209 P 0.4 3.1 0.4-0.8 0.4 6.2 0.2 0.2 2 Staph. 9.144 0.4-1.6 6.2 0.4 0.4 3.1 0.8 0.4 3 Strepto A 561 12.5-50 50 6.2 6.2 > 100 6.2 100 4 Strepto D.M. 19 1.6-3.1 50 1.6-3.1 6.2 100 6.2 50 5 B. subtilis 0.2-0.4 1.6 0.2-0.4 6.2 3.1 0.4 0.2 6 Bord. bronchis. 4.617 1.6-6.2 25 0.2-12.5 6.2 100 12.5 12.5 7 Ps. aeruginosa A.22 3.1-6.2 12.5 1.6-3.1 12.5 100 25 12.5 8 Ps. aeruginosa 72.345 3.1-6.2 12.5 1.6-3.1 12.5 100 25 6.2 9 Esch. coli 95 I.S.M. 0.4-0.8 0.2 1.6 6.2 3.1 1.6 10 Esch. coli 54.127 O.M.S. 0.2-0.4 1.6 0.2 3.1 6.2 6.2 3.1 11 Esch. coli 111 B4 0.2-0.4 1.6 0.2 3.1 6.2 3.1 3.1 12 Klebs. pneum. 10.031 0.2 0.8 0.2 0.4 3.1 0.4 0.2 13 Salm. typhi 0901 0.4-1.6 3.1 0.2 3.1 25 6.2 3.1 14 S. enteritidis Danysz 0.4-1.6 3.1 0.2 3.1 12.5 6.2 3.1 15 S. oranienburg 1066 12.5-25 > 100 6.2-12.5 25 > 100 100 > 100 16 Arizona 6.211 0.2-0.8 1.6 0.2 1.6 12.5 3.1 1.6 17 Berratia 1.6-3.1 12.5 3.1-12.5 25 > 100 3.1 0.8 18 Providentia 0223 3.1-12.5 100 1.6-3.1 25 > 100 50 > 100 19 Sh. sonnei I.P.S. 0.2-0.8 1.6 0.2 0.8 6.2 1.6 0.8 20 Pr. vulgaris 12-53 0.4-1.6 3.1 0.2 1.6 25 6.2 0.8 21 Pr. miribilis Nig 0.4-0.8 3.1 0.2 3.1 50 6.2 1.6 22 Pr. morganii A.236 0.2-0.8 0.8 0.2 1.6 3.1 3.1 0.8 In vitro, the fluorine-containing compounds described in Examples 20 to 42 have anti-bacterial properties which are even more marked than those of their chlorinecontaining homologues, as shown in Table 3 in which the activities of the most active acids are compared with those of oxolinic acid.
It is also evident from this table that the acids containing a fluorine atom in the 6-position are compounds having a broad spectrum, the anti-bacterial activities of which compounds, especially with respect to Proteus, Klebsiella, Serratia and Providentia, can be valuable in human and veterinary medicine.
The products of the following examples are especially singled out: Example 20.
1 - Ethyl - 6 - fluoro - 7 - (4 - methylpiperazinyl) - 4 - oxo - 1,4 - dihydro quinoline - 3 - carboxylic acid.
Example 22.
1 - Ethyl - 6 - fluoro - 7 - (4 - allylpiperazinyl) - 4 - oxo - 1,4 - dihydro - quinoline 3 - carboxylic acid.
Example 41.
1 - Vinyl - 6 - fluoro - 7 - (4 - methyl - piperazinyl) - 4 - oxo - 1,4 - dihydro quinoline - 3 - carboxylic acid.
These compounds have a remarkably low toxicity, as shown by the results recorded in Table 4 in which the 50% lethal doses (LDso) for mice are indicated, when the products are administered intravenously (i.v.) or orally (p.o.).
The activity of the compounds according to the invention against systemic infections in mice, caused by Staphylococcus 50,774, Streptococcus pyogenes A 65, Pseudomonas aeruginosa No. 12 and Escherichia coli P 5101, has been studied.
The infections were set up by intraperitoneal injection of a suspension of the bacterial culture corresponding to the germ studied. The products were administered orally at the time of infection, and 6 hours later. The mortality was observed for 14 days for Staph. aureus and for 7 days for the other germs.
The 50% effective dose (EDs) which protects 50% of the animals from death caused by the infection, and the EDgo which protects 90% of the animals, were thus determined. Oxolinic acid was used as the reference substance.
In these experiments, the 6-fluoroacids were the most effective and, amongst these, those of Examples 20 and 22 are preferred, as shown in Table 4 in which the minimum inhibitory concentrations (M.I.C.) of each of the compounds are also indicated for the germs used in the experimental infections. These two products have a very substantially greater activity than oxolinic acid in the models studied.
TABLE 3 (M.I.C. in g/cm )
Example 20 Example 22 Example 30 Example 31 Example 33 Ex. 40 Ex. 41 Oxolinic acid 1 Staph. 209 P 0.2 0.1-0.2 0.4 0.8 0.8 0.1 0.8 0.8 2 Staph. 9.144 0.2 0.2 0.4 0.8 1.6 1.6 0.8 0.8 3 Strepto A 561 0.8-3.1 1.6-3.12 3.1-6.2 12.5 6.2-12.5 12.5 25 25 4 Strepto D.M. 19 0.8-1.6 0.8-3.15 3.1-6.2 12.5 6.2-12.5 12.5 25 25 5 B. Subtilis 0.05-0.1 0.1-0.2 0.8 0.4 0.4 0.2 0.1 0.1 6 Bord. bronchis. 4.617 0.8-3.1 3.12 6.25 6.25 0.2 12.5 3.1 3.1 7 Ps. aeruginosa A.22 0.8 1.6-3.12 1.6 0.8-3.12 3.1 3.1 12.5 12.5 8 Ps. aeruginosa 72.345 0.8 3.12 1.6 0.4-3.12 3.1 6.2 6.2 6.2 9 Esch. coli 95 I.S.M. 0.1 0.1-0.4 0.1 0.2 0.4 0.8 0.1 0.1 10 Esch. coli 54.127 O.M.S. 0.1 0.1-0.8 0.8 0.2 0.4 0.8 0.4 0.4 11 Esch. coli 111 B4 0.05-0.1 0.2-0.8 0.8 0.2 0.4 0.8 0.4 0.4 12 Klebs. pneum. 10.031 0.05-0.1 0.1-0.2 0.8 0.1 0.1 0.8 0.1 0.1 13 Salm. typhi 0901 0.1 0.1-0.4 0.4 0.8 0.1 0.8 0.4 0.4 14 S. enteritidis Danysz 0.1-0.2 0.4 0.4 0.2 0.4-0.8 1.6 0.8 0.8 15 S. oranienburg 1066 3.1 6.2-12.5 6.2-12.5 12.5 12.5 100 25 25 16 Arizona 6.211 0.1-0.2 0.2-0.8 0.2-0.4 0.2 0.4 0.8 0.4 0.4 17 Serratia 0.8 0.025 0.2 0.2 0.05-0.4 3.1 0.8 0.8 18 Providentia 0223 0.8-1.6 1.6-6.2 0.8-1.6 1.6 12.5 25 25 25 19 Sh. Sonnei I.P.S. 0.01-0.02 0.1-0.2 0.2-0.4 0.1 0.2 0.8 0.2 0.2 20 Pr. vulgaris 12-53 0.1-0.4 0.2-0.4 0.2 0.2 0.2 0.8 0.05 0.05 21 Pr. mirabilis Nig 0.2-0.4 0.4-0.8 0.4 0.2 0.8-1.6 1.6 0.4 0.4 22 Pr. morganii A. 236 0.1-0.4 0.2 0.2 0.2 0.05-0.2 0.2 0.1 0.1 TABLE 4
Staph. aureus Strept. pyogenes P. aeruginosa E. coli 50,774 A. 65 No. 12 P 5101 LD50 Example (mg/kg) (mg/kg) (mg/kg) (mg/kg) (mg/kg) ED90 ED50 ED90 ED50 ED90 ED50 ED90 ED50 Example 9.3 2.9 103.3 65 11.5 7.8 2.8 1.8 20 i.v. : 350 M.I.C. 0.39 g/cm 3.13 g/cm 1.56 g/cm 0.1 g/cm p.o. > 2,000 Example 17 5.2 129.6 64.7 26.9 13.3 5.2 2.9 22 i.v. : 177 M.I.C. 0.39 g/cm 3.13 g/cm 6.25 g/cm 0.39 g/cm p.o. > 2,000 Oxolinic 110.7 53.2 > 100 > 100 142 70.1 45.1 17.0 acid i.v. : 177 M.I.C. 1.56 g/cm 100 g/cm 12.5 g/cm 0.2 g/cm p.o. > 2,000 The compound of Example 20, 1-ethyl-6-fluoro-7-(4-methylpiperazinyl)-4-oxo1,4-dihydro-quinoline-3-carboxylic acid, appears to be the most valuable because of its good bacteriological activity and its very low toxicity. In dogs, this product was very well tolerated on oral administration: the administration of a dose of 50 mg/kg did not cause any digestive disorder or any disorder of central nervous origin.
During experiments of this type, the blood of three dogs (A, B and C), which had received the above-mentioned dose by oral administration, was sampled over a period of time and the proportion of active compound was determined bacteriologically by means of Bacillus subtilis ATCC 6633. Table 5 gives the concentrations found as well as that for an animal (D) which had also received 25 mg of the compound of Example 20 by oral administration.
TABLE 5
Concentrations in g/cm of plasma after: Dose p.o. 0.5 hour 1 hour 2 hours 3 hours 4 hours 6 hours 8 hours 10 hours 24 hours A 2.6 3.4 7.7 10.8 9.8 8.4 6.4 5.1 2 B 4.6 19.2 23.4 20.6 18 13.2 8.8 4.5 0.3 50 mg/kg C 4.4 11.2 17.2 16.4 10.4 6.2 0.8 25 mg/kg D 2.6 7.2 7.8 6.5 6.1 4.1 2.7 1.6 0.1 As is frequently the case in this type of experiment, the individual variations were noted from animal to animal, but the plasma concentrations observed, during at least the first six hours, were compatible in all cases with the treatment of a systemic complaint caused by most of the bacteria studied.
The urine of the three animals (A, B and C) after 24 hours also had concentrations (c) which were very much greater than the minimum inhibitory concentrations: A (c=54.4 g/cm ), B (c=72 g/cm ) and C (c=61 g/cm ).
All these results make it possible to anticipate a good therapeutic action of the compounds of Examples 20 and 22, and more particularly of the first: 1-ethyl-6-fluoro7 - (4 - methylpiperazinyl) - 4 - oxo - 1,4 - dihydro - quinoline - 3 - carboxylic acid.
The compounds according to the invention can be used in human and veterinary medicine for the treatment of systemic or localised infectious diseases, such as infections of the urinary or bile ducts.
*In general, a daily dosage of 10 to 60 mg of the active compound per kg body weight is recommended for the treatment of infections caused by sensitive bacteria.
The daily dose can be divided into two, three or four administrations. Compositions containing the active compounds can be administered orally or by injection in a dose falling within the above range. The dosage may, of course, be varied according to the seriousness of the disease treated, and also as a function of age, sex, body weight and the species of animal concerned.
The compounds according to the invention are used as the free bases or as their physiologically acceptable acid addition salts in pharmaceutical compositions which additionally comprise an inert physiologically acceptable carrier. The carrier may be liquid or solid, organic or inorganic, and suitable for oral or parenteral administration and should be inert in the sense of not reacting with the active compounds. Suitable carriers are, for example, water, gelatine, lactose, starch, stearyl alcohol, magnesium stearate, talc, vegetable oils, benzyl alcohol, gums, propylene glycol and petroleum jelly.
For oral adminitsration, suitable forms of pharmaceutical composition are, for example, compressed tablets, dragees, capsules, pills and suspensions. In solid forms, for example capsules and compressed tablets, each dosage unit preferably contains 0.1 to 0.5 g of active compound and 0.1 to 0.5 g ofcarrier. Suitable carriers for such solid forms are, for example, lactose, starch, talc, gelatine and magnesium stearate.
Aqueous suspensions preferably contain 20 to 100 mg of active compound per cmt. Water-soluble high molecular weight compounds may be included in such suspensions in otder to stabilise them, such as cellulose esters and polyethvlene glycols.
Sweetening agents, aromatising agents and/or colourants may also be added.
Iniectable compositions preferably comprise solutions of the physiologically acceptable acid addition salts according to the invention in distilled water, the solutions containing from 0.2 to 1 g of the active compound per 5 or 10 cm, of the final solution.
If desired, such solutions mav contain the necessary quantity of sodium chloride to render the solution isotonic. The solutions can be presented in 5 or 10 cm5 ampoules which are sterilised in an autoclave. Equally, after sterile filtration, 5 or 10 cmS of the solution can be filled into the appropriate sized sterile ampoules and then subjected to lyophilisation.
Solutions such as iust described can also be used for local treatments in otc rhino-laryngoloey or ophthalmology. For this purpose they should be sterilised and may contain adjuvants, such as preservative agents, softening agents, emulsifiers, solubilisers, stabilisers, salts for controlling the osmotic pressure, and buffers.
The comnounds according to the invention can, as already stated, be used in veterinary medicine, for example in the forms described above or as additives in animal feeastuffs.

Claims (20)

WHAT WE CLAIM IS:
1. 6 - Halogeno - 1 - substituted - 7 - disubstituted - amino - 4 - oxo - 1,4dihydro-quinoline-3-carboxylic acids of formula I:
in which R1 is an alkyl group having up to 5 carbon atoms, an aralkyl group in which the alkyl group contains up to 5 carbon atoms, a vinyl or allyl group, or a hydroxy alkyl or halogenoalkyl group having up to 5 carbon atoms, R2 and R, are each an alkyl group having up to 5 carbon atoms or, together with the nitrogen atom to which they are attached, form a 5- or 6-membered heterocyclic ring containing the nitrogen atom and, optionally, another hetero atom, which heterocyclic ring may optionally be substituted, and X is a halogen atom, provided that R2 and Rg do not form an unsubstituted piperazinyl group when R1 is ethyl and X is fluorine, and their physiologically acceptable acid addition salts.
2. Compounds of formula I specified in claim 1, in which R1 is an alkyl group having up to 5 carbon atoms, benzyl, vinyl, allyl, or a hydroxyalkyl or halogenoalkyl group having up to 5 carbon atoms, and R2 and R3 together with the nitrogen atom to which they are attached, form a pyrrolidino, piperidino, hydroxypiperidino, morpholino, or piperazinyl group or a 4-substituted-piperazinyl group of the formula:
in which n is 0, 1, 2 or 3, R4 is hydrogen, a hydroxyl group (provided n is 2 or 3), an unsubstituted or substituted phenyl group, a vinyl group (provided n is 1, 2 or 3), or a formyl or acetyl group, and X is chlorine, fluorine or bromine, provided that R2 and Ra do not form an unsubstituted piperazinyl group when Rl is ethyl and X is fluorine.
3. Compounds of formula I specified in claim 1, in which Rt is a methyl, ethyl, benzyl, vinyl, allyl, 2-hydroxyethyl or 2-chloroethyl group, R2 and R, are each methyl groups or, together with the nitrogen atom to which they are attached, form a pyrrolidino, piperidino, hydroxypiperidino, morpholino, piperazinyl, 4-methyl-piperazinyl, 4allyl-piperazinyl, 4- (2-hydroxyethyl) -piperazinyl, 4-phenyl-piperazinyl, 4-benzylpiperazinyl or 4-formyl-piperazinyl group, and X is chlorine, fluorine or bromine, provided that R2 and R, do not form an unsubstituted piperazinyl group when R1 is ethyl and X is fluorine.
4. 6 - Chloro - 1 - ethyl - 7 - (4 - methyl - piperazinyl) - 4 - oxo -1,4 - dihydro- quinoline-3-carboxylic acid and its physiologically acceptable acid addition salts.
5. 6 - Fluoro - 1 - ethyl - 7 - (4 - methyl - piperazinyl) - 4 - oxo - 1,4 - dihydro- quinoline-3-carboxylic acid and its physiologically acceptable acid addition salts.
6. 6 - Chloro - 1 - ethyl - 7 - piperazinyl - 4 - oxo - 1,4 - dihydro - quinoline3-carboxylic acid and its physiologically acceptable acid addition salts.
7. 6 - Fluoro - 1 - ethyl - 7 - (4 - allyl - piperazinyl) - 4 - oxo - 1,4 - dihydroquinoline-3-carboxylic acid and its physiologically acceptable acid addition salts.
8. 6 - Fluoro - 1 - vinyl - 7 - (4 - methyl - piperazinyl) - 4 - oxo - 1,4 - dihydroquinoline-3 -carboxylic acid and its physiologically acceptable acid addition salts.
9. A pharmaceutical composition comprising at least one compound according to any of claims 1 to 8 and an inert, physiologically acceptable carrier.
10. A composition according to claim 9 in dosage unit form suitable for oral administration, each dosage unit containing from 0.1 to 0.5 g of the active compound(s).
11. A composition according to claim 9 in dosage unit form suitable for parenteral administration, each dosage unit containing from 0.2 to 1 g of the active compound(s).
12. A process for the preparation of a compound of formula I specified in claim 1, which comprises condensing a secondary amine of the formula:
in which R2 and R3 have the meanings specified in claim 1, with a 1-substituted-6halogeno - 7 - chioro - 4 - oxo 1,4 - dihydro - quinoline - 3 -carboxylic acid of the formula:
in which R1 and X have the meanings specified in daim 1, provided that R2 and Rs do not form an unsubstituted piperazinyl group when R1 is ethyl and X is fluorine.
13. A process according to claim 12, in which the reaction is carried out by heating the two reactants in the presence of an acceptor for the hydracid which is formed by the condensation.
14. A process according to claim 12 or 13, in which the reaction is carried out at a temperature of from 100 to 200"C.
15. A process according to any of claims 12 to 14, in which the reaction is carried out in the presence of an inert organic solvent having a boiling point of at least 100"C.
16. A process according to claim 15 in which the solvent is an aliphatic alcohol, glycol, a glycol ether, dimethylformamide, dimethylacetamide or dimethylsulphoxide.
17. A process according to claim 15, in which the solvent is pyridine or a methylated derivative thereof.
18. A process for the preparation of a compound of formula I specified in claim 1 in which Rl is a vinyl group and X is fluorine, which comprises a) alkylating 7 - chloro - 6 - fluoro - 3 - ethoxycarbonyl - 4 - oxo - 1,4 - dihydro quinoline of the formula:
by reaction with a 2-halogeno-ethanol in the presence of a base to form 7-chloro- 6-fluoro-3-ethoxycarbonyl-1-(2-hydroxyethyl)-4-oxo-1,4-dihydro-quinoline of the formula:
b) chlorinating the ester V to form 7-chloro-6-fluoro-3-ethoxycarbonyl-1-(2-chloro- ethyl)-4-oxo-1,4-dihydroquinoline of the formula
c) saponifying the compound VI with an excess of alkali metal hydroxide followed by neutralisation to form 7 - chloro - 6 - fluoro - 1 - vinyl - 4 - oxo - 1,4 - dihydr quinoline-3-carboxylic acid of the formula:
d) condensing the compound VII with a secondary amine of the formula:
in which R2 and R3 have the meanings specified in claim 1, to obtain the desired compound.
19. A process for the preparation of a compound of- formula I specified in claim 1 in which R1 is a vinyl group and X is fluorine, which comprises a) alkylating 7 - chloro - 6 - fluoro - 3 - ethoxycarbonyl - 4 - oxo - 1,4 - dihydro quinoline of the formula:
by reaction with a 2-halogeno-ethanol in the presence of a base to form 7-chloro6 - fluoro - 3 - ethoxycarbonyl - 1 - (2 - hydroxyethyl) - 4 - oxo - 1,4 - dihydr quinoline of the formula:
b) saponifying the compound V with an alkali metal hydroxide followed by acidifica tion to form 7 - chloro - 6 - fluoro - 1 - (2 - hydroxyethyl) - 4 - oxo - 1,4- dihydro-quinoline-3-carboxylic acid of the formula:
c) condensing the compound IX with a secondary amine of the formula:
in which R2 and R, have the meanings specified in claim 1, to form a 7-disubstituted - amino - 6 - fluoro - 1 - (2 - hydroxyethyl) - 4 - oxo - 1,4 - dihydro quinoline-3-carboxylic acid of the formula:
d) chlorinating the acid X and then esterifying the free carboxyl group of the product to form a 7 - disubstituted - amino - 6 - fluoro - 1 - (2 - chloroethyl) - 3 ethyoxylcarbonyl-4-oxo- 1,4-dihydro-quinoline of the formula:
e) saponifying the compound XI with an alkali metal hydroxide followed by neutralisa tion to obtain the desired compound.
20. A process for the preparation of a compound according to claim I substantially as herein described in any of the Examples.
GB39197/77A 1977-09-20 1977-09-20 1,4-dihydro-quinoline-3-carboxylic acid derivatives process for their preparation and composition containing them Expired GB1598915A (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GB39197/77A GB1598915A (en) 1977-09-20 1977-09-20 1,4-dihydro-quinoline-3-carboxylic acid derivatives process for their preparation and composition containing them
SE7809411A SE444566B (en) 1977-09-20 1978-09-07 7-DIALKYLAMINE-6-HALOGEN-4-OXO-1,4-DIHYDROQINOLINE-3-CARBOXYLIC ACID, PROCEDURES FOR PREPARING THEREOF AND PHARMACEUTICAL PREPARATION OF THEREOF
FR7825937A FR2403339A1 (en) 1977-09-20 1978-09-08 6-Halo-7-tert. amino-4-oxo-quinoline carboxylic acid derivs. - broad spectrum antibacterials and growth promoters for animals
CA000311364A CA1175836A (en) 1977-09-20 1978-09-15 Production of 1,4-dihydroquinoline-3-carboxylic acid derivatives
US05/942,635 US4292317A (en) 1977-09-20 1978-09-15 1,4-Dihydro-quinoline-3-carboxylic acid derivatives, process for their preparation and compositions containing them
ES473486A ES473486A1 (en) 1977-09-20 1978-09-19 6-Halo-7-tert. amino-4-oxo-quinoline carboxylic acid derivs. - broad spectrum antibacterials and growth promoters for animals
AU39962/78A AU520458B2 (en) 1977-09-20 1978-09-19 l, 4-DIHYDRO-QUINOLINE-3-CARBOXYLIC ACID DERIVATIVES
BE2057287A BE870576A (en) 1977-09-20 1978-09-19 NEW DIALKYLAMINO-7 HALOGENO-6 OXO-4-DIHYDRO-1,4-QUINOLEINE-3-CARBOXYLIC ACIDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM
JP11471278A JPS5466686A (en) 1977-09-20 1978-09-20 Quinoline-3-carboxylic acid derivative, its preparation, and pharmaceutical composition containig the same
NLAANVRAGE7809591,A NL190520C (en) 1977-09-20 1978-09-20 Position 1 substituted, 7-substituted amino-6-halo-4-oxo-1,4-dihydroquinoline-3-carboxylic acids and pharmaceutical preparations containing them.
DE19782840910 DE2840910A1 (en) 1977-09-20 1978-09-20 7-DIALKYLAMINO-6-HALOGEN-4-OXO-1,4-DIHYDRO-3-QUINOLINECARBONIC ACIDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL AGENTS CONTAINING THEM
FR8120346A FR2498931A1 (en) 1977-09-20 1981-10-29 MEDICAMENT CONSISTING OF THE ACID ETHYL-1 FLUORO-6 PIPERAZINYL-7-OXO-4-DIHYDRO-1,4 QUINOLIN-3-CARBOXYLIC AND ITS SALTS OF ADDITION OF NON-TOXIC ACIDS PHARMACEUTICALLY ACCEPTABLE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB39197/77A GB1598915A (en) 1977-09-20 1977-09-20 1,4-dihydro-quinoline-3-carboxylic acid derivatives process for their preparation and composition containing them

Publications (1)

Publication Number Publication Date
GB1598915A true GB1598915A (en) 1981-09-23

Family

ID=10408225

Family Applications (1)

Application Number Title Priority Date Filing Date
GB39197/77A Expired GB1598915A (en) 1977-09-20 1977-09-20 1,4-dihydro-quinoline-3-carboxylic acid derivatives process for their preparation and composition containing them

Country Status (3)

Country Link
AU (1) AU520458B2 (en)
BE (1) BE870576A (en)
GB (1) GB1598915A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0216245A1 (en) * 1985-09-10 1987-04-01 Kyorin Pharmaceutical Co., Ltd. Quinolonecarboxylic acid derivatives and process for their preparation
WO2001036408A1 (en) * 1999-11-15 2001-05-25 New Pharma Research Sweden Ab Compounds with antibacterial and antiparasitic properties
US9079922B2 (en) 2011-11-08 2015-07-14 Actelion Pharmaceuticals Ltd 2-oxo-oxazolidin-3,5-diyl antibiotic derivatives

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551456A (en) * 1983-11-14 1985-11-05 Merck & Co., Inc. Ophthalmic use of norfloxacin and related antibiotics
GB8512143D0 (en) * 1985-05-14 1985-06-19 Beecham Group Plc Method of treatment
DE3608745A1 (en) * 1985-07-24 1987-01-29 Bayer Ag BACTERICIDAL PREPARATIONS FOR APPLICATION IN THE VETERINE MEDICINE AREA
FR2655545B1 (en) 1989-12-11 1994-06-10 Rhone Poulenc Sante NEW THERAPEUTIC APPLICATION OF FLUOROQUINOLONE DERIVATIVES.
US5532239A (en) * 1993-08-02 1996-07-02 Assistance Publique - Hopitaux De Paris Therapeutic application of fluoroquinolone derivatives
US7973022B2 (en) 2006-02-17 2011-07-05 Idexx Laboratories, Inc. Fluoroquinolone carboxylic acid salt compositions
US20070197548A1 (en) 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone compositions

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0216245A1 (en) * 1985-09-10 1987-04-01 Kyorin Pharmaceutical Co., Ltd. Quinolonecarboxylic acid derivatives and process for their preparation
WO2001036408A1 (en) * 1999-11-15 2001-05-25 New Pharma Research Sweden Ab Compounds with antibacterial and antiparasitic properties
US6967205B1 (en) 1999-11-15 2005-11-22 New Pharma Research Sweden Ab Compounds with antibacterial and antiparasitic properties
US9079922B2 (en) 2011-11-08 2015-07-14 Actelion Pharmaceuticals Ltd 2-oxo-oxazolidin-3,5-diyl antibiotic derivatives

Also Published As

Publication number Publication date
AU3996278A (en) 1980-03-27
AU520458B2 (en) 1982-02-04
BE870576A (en) 1979-03-19

Similar Documents

Publication Publication Date Title
US4292317A (en) 1,4-Dihydro-quinoline-3-carboxylic acid derivatives, process for their preparation and compositions containing them
KR870001016B1 (en) Process for preparing 6-fluoro-1,4-dihydro-4-oxo-7-substituted piperazinylquinoline-3-carboxylic acid derivatives
US4017622A (en) Piperazine derivatives
US4341784A (en) Naphthyridine derivatives
US4359578A (en) Naphthyridine derivatives and salts thereof useful as antibacterial agents
US4620007A (en) 6-fluoro-7-chloro-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid
KR910006806B1 (en) Process for preparing quinaline derivatives
FI77855C (en) FOERFARANDE FOER FRAMSTAELLNING AV THERAPEUTISKT ANVAENDBARA 6-FLUOR-1,4-DIHYDRO-4-OXO-3-KINOLINKARBOXYLSYRADERIVAT.
EP0131839A1 (en) Quinoline antibacterial compounds
HU198198B (en) Process for production of new derivatives of quinoline and medical preparatives containing them as active substance
HU199821B (en) Process for production of derivatives of in 8 position substituated quinoline carbonic acid and medical compositions containing them
EP0154780B1 (en) Quinoline antibacterial compounds
GB1598915A (en) 1,4-dihydro-quinoline-3-carboxylic acid derivatives process for their preparation and composition containing them
US3962443A (en) Antibacterial pharmaceutical compositions and processes for preparation thereof
EP0160284B1 (en) Quino-benoxazine antibacterial compounds
EP0090424B1 (en) New quinolone compounds and preparation thereof
JPH02247176A (en) Benzo(b)(1,8)naphthyridine derivative, preparation thereof, and composition containing same
EP0181521A1 (en) Antimicrobial 1-substituted Phenyl-4-oxoquinoline-3-carboxylic acid compounds
IE872444L (en) Pyrido-benzoxadiazine derivatives
NZ226574A (en) 5-amino- or 5-halo-1-cyclopropyl-6-fluoro-7-(1- piperazinyl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid derivatives; pharmaceutical compositions and methods of preparation and treatment
US4720495A (en) Benzo[ij]quinolizine-2-carboxylic acids useful for treating bacterial infection
EP0162333B1 (en) Quino-benzothiazine antibacterial compounds
JP3080629B2 (en) Benzo [b] [1,8] naphthyridine derivatives, their preparation and compositions containing them
EP0315827B1 (en) Derivatives of quinolinecarboxylic acid
KR900009024B1 (en) Quinolone carobxylic acid compounds and pharmaceutical use thereof

Legal Events

Date Code Title Description
PS Patent sealed
746 Register noted 'licences of right' (sect. 46/1977)
747 Application for cancellation of 'licences of right' in the register (sect. 47/1977)
747C Notice that the entry in the register 'licence of right' was cancelled (sect. 47/1977)
PE20 Patent expired after termination of 20 years

Effective date: 19980529